Single agent bevacizumab for myelofibrosis: Results of the myeloproliferative disorders research consortium trial

Haematologica

Volumn 98, Issue 9, 2013, Pages 1421-1423

  Mesa, Ruben A ^a   Silver, Richard T ^b   Verstovsek, Srdan ^c   Mascarenhas, John ^d   Kessler, Craig M ^e   Rondelli, Damiano ^f   Goldberg, Judy D ^g   Marchioli, Roberto ^h   Demakos, Erin P ^d   Silverman, Lewis R ^d   Hoffman, Ronald ^d  

^a MAYO CLINIC   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF ILLINOIS   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Laboratorio Angela Valenti dei Fattori Genetici e Ambientali di Rischio Trombotico   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN;

ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; DEATH; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART FAILURE; HUMAN; INFECTION; LIVER FUNCTION; MALE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MYELOFIBROSIS; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA; SIDE EFFECT; THROMBOCYTHEMIA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PRIMARY MYELOFIBROSIS;

EID: 84883616325     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.083337     Document Type: Article

References (38)

1. Paulsson K, Johansson B. High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2009;48(8):637-60.
2. Raimondi SC, Pui C-H, Hancock ML, Behm FG, Filatov L, Rivera GK. Heterogeneity of hyperdiploid (51-67) childhood acute lymphoblastic leukemia. Leukemia. 1996;10(2): 213-24.
3. Forestier E, Johansson B, Gustafsson G, Borgström G, Kerndrup G, Johannsson J, Heim S. Prognostic impact of karyotypic findings in childhood acute lymphoblastic leukaemia: a Nordic series comparing two treatment periods. Br J Haematol. 2000; 110(1):147-53.
4. Heerema NA, Sather HN, Sensel MG, Zhang T, Hutchinson RJ, Nachman JB, et al. Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). J Clin Oncol. 2000;18(9):1876-87.
5. Moorman AV, Richards SM, Martineau M, Cheung KL, Robinson HM, Jalali GR, et al. Outcome heterogeneity in childhood highhyperdiploid acute lymphoblastic leukemia. Blood. 2003;102(8):2756-62.
6. Zachariadis V, Gauffin F, Kuchinskaya E, Heyman M, Schoumans J, Blennow E, et al. The frequency and prognostic impact of dic(9;20)(p13.2;q11.2) in childhood B-cell precursor acute lymphoblastic leukemia: results from the NOPHO ALL-2000 trial. Leukemia. 2011;25(4):622-8.
7. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE, et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol. 2010;11(6): 429-38.
8. Norén-Nyström U, Roos G, Bergh A, Botling J, Lönnerholm G, Porwit A, et al. Bone marrow fibrosis in childhood acute lymphoblastic leukemia correlates to biological factors, treatment response and outcome. Leukemia. 2008;22(3):504-10.
9. Sharathkumar A, DeCamillo D, Bhambhani K, Cushing B, Thomas R, Mohamed AN, et al. Children with hyperdiploid but not triple trisomy (+4,+10,+17) acute lymphoblastic leukemia have an increased incidence of extramedullary relapse on current therapies: a single institution experience. Am J Hematol. 2008;83 (1):34-40.
10. Pui C-H, Raimondi SC, Dodge RK, Rivera GK, Fuchs LA, Abromowitch M, et al. Prognostic importance of structural chromosomal abnormalities in children with hyperdiploid (>50 chromosomes) acute lymphoblastic leukemia. Blood. 1989;73(7): 1963-7.
11. Groupe Français de Cytogénétique Hématologique. Collaborative study of karyotypes in childhood acute lymphoblastic leukemias. Leukemia. 1993;7(1):10-9.
12. Sutcliffe MJ, Shuster JJ, Sather HN, Camitta BM, Pullen J, Schultz KR, et al. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard-risk B-precursor acute lymphoblastic leukemia: a Children's Oncology Group (COG) initiative. Leukemia. 2005;19(5):734-40.
13. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz M, et al. Risk-and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. 2007;109(3):926-35.
14. Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Söderhäll S, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010; 24(2):345-54.
15. Harrison CJ, Moorman AV, Barber KE, Broadfield ZJ, Cheung KL, Harris RL, et al. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics group study. Br J Haematol. 2005;129(4):520-30.
16. Forestier E, Holmgren G, Roos G. Flow cytometric DNA index and karyotype in childhood lymphoblastic leukemia. Anal Cell Pathol. 1998;17(3):145-56.
17. Mitelman F, Johansson B, Mertens F. Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer. http://cgap.nci.nih.gov/Chromosomes/Mit elman (accessed July 3, 2012).
18. Pui C-H, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166-78.
19. Uckun FM, Sensel MG, Sather HN, Gaynon PS, Arthur DC, Lange BJ, et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Childrens Cancer Group. J Clin Oncol. 1998;16(2):527-35.
20. Dombret H, Gabert J, Boiron J-M, Rigal-Huguet F, Blaise D, Thomas X, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357-66.
21. Heerema NA, Harbott J, Galimberti S, Camitta BM, Gaynon PS, Janka-Schaub G, et al. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. Leukemia. 2004;18(4):693-702.
22. Rieder H, Ludwig W-D, Gassmann W, Maurer J, Janssen JW, Gökbuget N, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol. 1996;95(4):678-91.
23. Wetzler M, Dodge RK, Mrozek K, Stewart CC, Carroll AJ, Tantravahi R, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol. 2004;124(3):275-88.
24. Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, et al. Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2005;106(13):4043-9.
25. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005;128(6):797-804.
26. Pui C-H, Raimondi SC, Borowitz MJ, Land VJ, Behm FG, Pullen DJ, et al. Immunophenotypes and karyotypes of leukemic cells in children with Down syndrome and acute lymphoblastic leukemia. J Clin Oncol. 1993;11(7):1361-7.
27. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalová K, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood. 2008;111(3):1575-83.
28. Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood. 2010;115(5):1006-17.
29. Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. Blood. 2010; 116(7):1045-50.
30. Loudin MG, Wang J, Leung HC, Gurusiddappa S, Meyer J, Condos G, et al. Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia. 2011;25(10):1555-63.
31. Herou E, Biloglav A, Johansson B, Paulsson K. Partial 17q gain resulting from isochromosomes, unbalanced translocations, and complex rearrangements is associated with gene overexpression, older age, and shorter overall survival in high hyperdiploid childhood acute lymphoblastic leukemia. Leukemia. 2013;27(2):493-6.
32. Harris MB, Shuster JJ, Carroll A, Look AT, Borowitz MJ, Crist WM, et al. Trisomy of leukemic cell chromosomes 4 and 10 identifies children with B-progenitor cell acute lymphoblastic leukemia with a very low risk of treatment failure: a Pediatric Oncology Group study. Blood. 1992;79 (12):3316-24.
33. Kersey JH. Fifty years of studies of the biology and therapy of childhood leukemia. Blood. 1997;90(11):4243-51.
34. Paulsson K, Forestier E, Lilljebjörn H, Heldrup J, Behrendtz M, Young BD, et al. Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA. 2010;107(50): 21719-24.
35. Heerema NA, Raimondi SC, Anderson JR, Biegel J, Camitta BM, Cooley LD, et al. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2007;46(7):684-93.
36. Onodera N, McCabe NR, Rubin CM. Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. Blood. 1992;80(1):203-8.
37. Paulsson K, Panagopoulos I, Knuutila S, Jee KJ, Garwicz S, Fioretos T, et al. Formation of trisomies and their parental origin in hyperdiploid childhood acute lymphoblastic leukemia. Blood. 2003;102(8):3010-5.
38. Paulsson K, Mörse H, Fioretos T, Behrendtz M, Strömbeck B, Johansson B. Evidence for a single-step mechanism in the origin of hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2005;44(2):113-22.